|
| ASTRAZENECA ANNOUNCES RESULTS OF RECENTIN HORIZON II PHASE III TRIAL IN METASTATIC COLORECTAL CANCER |
|
| AstraZeneca today announced the top-line results of the HORIZON II Phase III study evaluating RECENTIN (cediranib) for the first-line treatment of metastatic colorectal cancer (mCRC). Cediranib met the co-primary endpoint of improving progression-free survival (PFS) but showed no improvement in overall survival (OS). |
|
 View full press release |
|
| This email has been sent via AstraZeneca's email alert service. Update your email preferences, unsubscribe from this service or contact us. |
|
No comments:
Post a Comment